Cancer Family
Malignant Skin Neoplasm
CI-CAN-00000250Explore in graph →
320 active trials14 approved drugs64 evidence items
- NCIt
- C2920
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000250Explore in graph →
Clinical trials
1,248 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (202)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00089180 | T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant | completed | Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT01236573 | Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes | terminated | Phase 1 / Phase 2 | 34 | National Institutes of Health Clinical Center (CC)NIH | 1 | Nov 26, 2015 |
| clinicaltrials |
| NCT00610311 | Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00612222 | Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00923195 | Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00665470 | Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Oct 19, 2015 | clinicaltrials |
| NCT01495572 | Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Oct 15, 2015 | clinicaltrials |
| NCT00403377 | Investigation of a Behavioral Substitute for Sunbathing | completed | Phase 1 / Phase 2 | 307 | University of Massachusetts, WorcesterOTHER | 1 | Oct 1, 2015 | clinicaltrials |
| NCT00131937 | Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2015 | clinicaltrials |
| NCT01729663 | Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients | unknown | Phase 2 / Phase 3 | 108 | Laboratorio Pablo Cassara S.R.L.INDUSTRY | 1 | Sep 2, 2015 | clinicaltrials |
| NCT00866177 | MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 2 | 167 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2015 | clinicaltrials |
| NCT00274651 | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas(PXD101-CLN-6) | terminated | Phase 2 | 53 | Valerio TherapeuticsINDUSTRY | 5 | Jul 28, 2015 | clinicaltrials |
| NCT00431912 | A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma | completed | Phase 2 | 25 | Valerio TherapeuticsINDUSTRY | 4 | Jul 8, 2015 | clinicaltrials |
| NCT00563290 | Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia | completed | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2015 | clinicaltrials |
| NCT01843998 | Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL) | withdrawn | Phase 2 | 0 | Stefan Schieke MDOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00129415 | Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions | terminated | Phase 1 / Phase 2 | 28 | University of MichiganOTHER | 1 | May 22, 2015 | clinicaltrials |
| NCT00885534 | Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma | completed | Phase 2 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT00278018 | Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid Tumors | terminated | Phase 1 / Phase 2 | 20 | Hadassah Medical OrganizationOTHER | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00367042 | Study to Determine if Tissue Scored With a Scalpel Results in Any Noticeable Marks | completed | Phase 2 / Phase 3 | 98 | University of California, DavisOTHER | 1 | Apr 16, 2015 | clinicaltrials |
| NCT00003210 | Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease | completed | Phase 2 | 105 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00099593 | Immunization Against Tumor Cells in Sezary Syndrome | completed | Phase 2 | 17 | University of PittsburghOTHER | 1 | Mar 25, 2015 | clinicaltrials |
| NCT00054691 | ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin | completed | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2015 | clinicaltrials |
| NCT01198665 | RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas(RADCHOP) | completed | Phase 1 / Phase 2 | 46 | Samsung Medical CenterOTHER | 1 | Mar 3, 2015 | clinicaltrials |
| NCT01369888 | Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jan 27, 2015 | clinicaltrials |
| NCT00470470 | Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01465815 | Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN) | withdrawn | Phase 1 / Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 19, 2014 | clinicaltrials |
| NCT00185965 | CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas | completed | Phase 1 / Phase 2 | 30 | Ronald LevyOTHER | 1 | Aug 1, 2014 | clinicaltrials |
| NCT00101348 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2014 | clinicaltrials |
| NCT02154451 | Transient Infrared Imaging for Early Detection of Skin Cancer | unknown | Phase 1 / Phase 2 | 400 | Skinfrared LLCOTHER | 1 | Jun 3, 2014 | clinicaltrials |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00054639 | Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT02142335 | Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma | unknown | Phase 2 | 17 | California Cancer Assocaties for Research & ExcellenceOTHER | 1 | May 20, 2014 | clinicaltrials |
| NCT00492089 | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00521092 | Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 5, 2014 | clinicaltrials |
| NCT00863395 | Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma(CTCL) | terminated | Phase 1 / Phase 2 | 6 | University of MinnesotaOTHER | 1 | Mar 31, 2014 | clinicaltrials |
| NCT02080962 | Hypofractionated Radiotherapy for Nonmelanoma Skin Cancer | terminated | Phase 2 | 10 | Barretos Cancer HospitalOTHER | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00004922 | Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00079131 | Oblimersen in Treating Patients With Merkel Cell Carcinoma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00068783 | S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT01464957 | Skin Cancer Prevention in a Pediatric Population | completed | Phase 2 | 867 | University of Colorado, DenverOTHER | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00005982 | 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00005080 | 506U78 in Treating Patients With Lymphoma | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00052377 | Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00509496 | Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes | terminated | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jan 15, 2013 | clinicaltrials |
| NCT00509288 | Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 28, 2012 | clinicaltrials |
| NCT00699296 | Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma | terminated | Phase 2 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 27, 2012 | clinicaltrials |
| NCT00168064 | Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides | completed | Phase 2 | 260 | Yaupon TherapeuticsINDUSTRY | 1 | Oct 31, 2012 | clinicaltrials |
| NCT00003549 | S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer | completed | Phase 2 | 80 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 8, 2012 | clinicaltrials |
| NCT00969085 | Trial of Curcumin in Cutaneous T-cell Lymphoma Patients | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 7, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Dec 4, 2015source: clinicaltrials